首页> 外文期刊>Annals of surgical oncology >The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival
【24h】

The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival

机译:原发性肿瘤位置在同步转移性结直肠癌中的影响:转移性位点的差异和生存

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose We explored differences in survival between primary tumor locations, hereby focusing on the role of metastatic sites in synchronous metastatic colorectal cancer (mCRC). Methods Data for patients diagnosed with synchronous mCRC between 1989 and 2014 were retrieved from the Netherlands Cancer registry. Relative survival and relative excess risks (RER) were analyzed by primary tumor location (right colon (RCC), left colon (LCC), and rectum). Metastatic sites were reported per primary tumor location. Survival was analyzed for metastatic sites combined and for single metastatic sites. Results In total, 36,297 patients were included in this study. Metastatic sites differed significantly between primary tumor locations, with liver-only metastases in 43%, 54%, and 52% of RCC, LCC, and rectal cancer patients respectively (p < 0.001). Peritoneal metastases were most prevalent in RCC patients (33%), and lung metastases were most prevalent in rectal cancer patients (28%). Regardless of the location of metastases, patients with RCC had a worse survival compared with LCC (RER 0.81, 95% CI 0.78-0.83) and rectal cancer (RER 0.73, 95% CI 0.71-0.76). The survival disadvantage for RCC remained present, even in cases with metastasectomy for liver-only disease (LCC: RER 0.66, 95% CI 0.57-0.76; rectal cancer: RER 0.84, 95% CI 0.66-1.06). Conclusions This study showed significant differences in relative survival between primary tumor locations in synchronous mCRC, which can only be partially explained by distinct metastatic sites. Our findings support the concept that RCC, LCC and rectal cancer should be considered distinct entities in synchronous mCRC.
机译:目的,我们探讨了原发性肿瘤位置之间存活的差异,从而关注转移位点在同步转移性结肠直肠癌(MCRC)中的作用。方法从荷兰癌症登记处检索1989年至2014年间诊断有同步MCRC的患者的数据。通过原发性肿瘤位置(右结肠(RCC),左结肠(LCC)和直肠)分析相对存活和相对过量的风险(RER)。每次原发性肿瘤位置报告转移性位点。分析了组合和单一转移位点的转移性位点的存活。结果总计36,297名患者纳入本研究。原发性肿瘤位置之间的转移性位点分别在肝脏肿瘤位置的肝脏转移中显着不同,分别为43%,54%和52%的RCC,LCC和直肠癌患者(P <0.001)。腹膜转移在RCC患者中最普遍(33%),直肠癌患者中最普遍的肺转移(28%)。无论转移的位置如何,RCC患者的存活率与LCC(RER 0.81,95%CI 0.78-0.83)和直肠癌(RER 0.73,95%CI 0.71-0.76)。即使在肝脏疾病疾病的转移术病例中,RCC的存活缺点仍然存在(LCC:RER 0.66,95%CI 0.57-0.76;直肠癌:RES 0.84,95%CI 0.66-1.06)。结论该研究表明同步MCRC中原发性肿瘤位置之间的相对存活差异显着差异,其只能通过不同的转移性位点部分解释。我们的调查结果支持CCC,LCC和直肠癌的概念应该被认为是同步MCRC中的不同实体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号